Literature DB >> 8428339

Oncogenes in prostate cancer. An update.

D M Peehl1.   

Abstract

Oncogenes have been implicated in the carcinogenic development of many diverse types of human malignancies. For some cancers, the expression of specific oncogenes has been shown to have diagnostic or prognostic value. By contrast currently, no oncogene has been correlated conclusively with the initiation or progression of prostate cancer. The ras oncogene has been investigated the most thoroughly for its involvement in prostate cancer, but ras does not appear to play a significant role in the development of this malignancy. Several years ago, limited studies hinted at the possibility of overexpression of the myc oncogene and aberrant expression of the sis oncogene in prostate cancer, but additional studies to clarify the involvement of these oncogenes have not been done. Oncogenic activity of growth factors or growth factor receptors in prostate cancer has been suggested but not amply demonstrated. Current dogma indicates that oncogenes exist in prostate cancer, but these will be identified only by more intensive investigation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8428339     DOI: 10.1002/1097-0142(19930201)71:3+<1159::aid-cncr2820711439>3.0.co;2-u

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

1.  Expression of mitogen-activated protein kinase phosphatase-1 in the early phases of human epithelial carcinogenesis.

Authors:  M Loda; P Capodieci; R Mishra; H Yao; C Corless; W Grigioni; Y Wang; C Magi-Galluzzi; P J Stork
Journal:  Am J Pathol       Date:  1996-11       Impact factor: 4.307

2.  Different patterns of DNA alterations detected by restriction landmark genomic scanning in heterogeneous prostate carcinomas.

Authors:  N Konishi; Y Hiasa; M Nakamura; Y Kitahori; K Matsubara; H Nagai
Journal:  Am J Pathol       Date:  1997-01       Impact factor: 4.307

Review 3.  Molecular biology of prostate cancer.

Authors:  X B Shi; P H Gumerlock; R W deVere White
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

Review 4.  Prostate cancer progression. Implications of histopathology.

Authors:  J L Ware
Journal:  Am J Pathol       Date:  1994-11       Impact factor: 4.307

5.  Intratumor cellular heterogeneity and alterations in ras oncogene and p53 tumor suppressor gene in human prostate carcinoma.

Authors:  N Konishi; Y Hiasa; H Matsuda; M Tao; T Tsuzuki; I Hayashi; Y Kitahori; T Shiraishi; R Yatani; J Shimazaki
Journal:  Am J Pathol       Date:  1995-10       Impact factor: 4.307

Review 6.  Targeting prostate cancer based on signal transduction and cell cycle pathways.

Authors:  John T Lee; Brian D Lehmann; David M Terrian; William H Chappell; Franca Stivala; Massimo Libra; Alberto M Martelli; Linda S Steelman; James A McCubrey
Journal:  Cell Cycle       Date:  2008-06-16       Impact factor: 4.534

7.  U94 alters FN1 and ANGPTL4 gene expression and inhibits tumorigenesis of prostate cancer cell line PC3.

Authors:  Ekwere T Ifon; Alan L Y Pang; Warren Johnson; Kathleen Cashman; Sharon Zimmerman; Sumitra Muralidhar; Wai-Yee Chan; John Casey; Leonard Jason Rosenthal
Journal:  Cancer Cell Int       Date:  2005-06-22       Impact factor: 5.722

8.  Down-regulation of c-Myc following MEK/ERK inhibition halts the expression of malignant phenotype in rhabdomyosarcoma and in non muscle-derived human tumors.

Authors:  Francesco Marampon; Carmela Ciccarelli; Bianca M Zani
Journal:  Mol Cancer       Date:  2006-08-09       Impact factor: 27.401

9.  P53 tumour-suppressor gene mutations are mainly localised on exon 7 in human primary and metastatic prostate cancer.

Authors:  R Dahiya; G Deng; K M Chen; R M Chui; P C Haughney; P Narayan
Journal:  Br J Cancer       Date:  1996-07       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.